欧洲国家使用的政策措施和工具来增加生物类似药的吸收:系统审查
Sara Machado1, Agostinho Cruz2, Pedro Lopes Ferreira3,4
1ESS, Polytechnic of Porto, Porto, Portugal.
Frontiers in public health
|March 14, 2024
概括
欧洲国家利用各种政策措施来促进生物类似药的采用. 定价法规和处方指南是增加这些成本效益治疗的市场份额的常见策略.
科学领域:
- 卫生政策 卫生政策
- 药物经济学 药物经济学
- 药品市场分析 药品市场分析
背景情况:
- 生物类似药物为医疗保健系统的可持续性提供了重大潜力.
- 生物类似药物利用率在欧洲各国存在差异.
研究的目的:
- 确定和系统化欧洲国家使用的政策措施和工具,以增强生物类似药的市场份额.
主要方法:
- 按照PRISMA 2020指南进行了系统审查.
- 在Medline-PubMed,Web of Science和ScienceDirect数据库中对2006年1月至2023年11月期间发表的英语文章进行了搜索.
- 排除标准包括有针对性的评论,信件,报告,社论和意见稿.
主要成果:
- 对涵盖28个欧洲国家的13个符合条件的文章的分析显示,价格监管措施的广泛使用 (27个国家).
- 招标,价格链接和内部参考定价经常被使用,招标常见于住院生物类药物采购.
- 还确定了处方指南,医生激励,配额和国际非专有名称处方.
结论:
- 自动替代并没有得到广泛的采用,这凸显了可互换和切换政策日益重要的重要性.
- 领先国家的成功策略可以作为未来欧洲生物类似药市场发展的典范.
相关概念视频
Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
Drug Control Governance: Regulatory Bodies and Their Impact
158
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
158
Biopharmaceutics and Pharmacokinetics: Overview
2.0K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.0K
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Pharmacovigilance
830
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
830


